MedTech Dive September 29, 2023
The analysis of U.S. insurance claims found people on GLP-1 therapy wear their FreeStyle Libre sensors more.
Dive Brief:
- Abbott’s analysis of U.S. pharmacy data has shown people on GLP-1 therapy wear their FreeStyle Libre sensors more.
- The rise of new GLP-1 treatments for diabetes and obesity has raised questions about whether the drug class will cut adherence to continuous glucose monitors such as Abbott’s FreeStyle Libre.
- However, the Abbott analysis suggests GLP-1 therapy has the opposite effect, leading analysts at Wells Fargo Securities to tell investors the drug class “could be a modest accelerator for Libre.”
Dive Insight:
The Food and Drug Administration first approved a GLP-1 receptor agonist in 2005. Interest in the drug class —...
Today's Sponsors
Today's Sponsor